Product Images Tamsulosin Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Tamsulosin Hydrochloride NDC 70518-2052 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Remedy_Label - Remedy Label
Tamsulosin HCI is a prescription medication in capsule form with a strength of 0.4 mg. The package contains 90 capsules and should be kept out of the reach of children. Directions for use are provided in the package insert. The medication should be stored within the temperature range of 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) [See USP]. The medication was repackaged by RemedyRepack Inc., Indiana, PA 15701, 724.466.8762. The LOT # and expiry date are not available in the provided text.*
Tamsulosin HCl 0.4mg 70518 2052 01
Tamsulosin HCI is a medication that comes in capsules that contain 0.4mg. It is available in a package of 30 and requires a prescription to be acquired. The medication is manufactured by Aurcbindo in India and should be kept out of the reach of children. The lot number and NDC number are also provided on the package. Directions for use are provided in the package insert, and the medication should be stored at a temperature between 20-26°C, with excursions permitted to 15-30°C. The medication has been repackaged by RemedyRepack Inc. based in Indiana, PA.*
Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1
This is a figure showing the mean plasma concentration of Tamsulosin Hydrochloride following single-dose administration of Tamsulosin Hydrochloride Capsules 0.4 mg under fasted and fed conditions over a period of time in hours. There is no further information available.*
Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2
The figure shows the mean change from baseline in the total AUA symptom score on a scale of 0 to 35 for Study 1. The treatment groups included -OO-0-08mg_~A= A -A04my_ and O30 placebo. The duration of treatment was 758, 693, 665, 637, 619, and 616 weeks, respectively. Data for the mean change are presented at weeks 0, 1, 2, 4, 10, 13 using LOCF.*
Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3
Figure 2B shows the mean change from baseline in the total American Urological Association (AUA) symptom score (0 to 35) observed in Study 2. The treatment options included 0.08mg LNt, 0.4mg, and placebo. The study lasted for a duration of weeks represented in the X-axis. However, no information about the study results is provided.*
Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4
The description for this image is: "Mean Increase in Peak Urine Flow Rate (in L/Sec) Study 1" with a graph showing the treatment, mean change in mL/sec, and duration of treatment in weeks.*
Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5
The text is showing a figure related to a study that measures the mean increase in peak urine flow rate in mL/sec. It is labeled as Figure 3B and relates to Study 2. The figure displays different treatment durations in weeks and their corresponding values for the urine flow rate. There is additional text represented in the figure, but it cannot be evaluated due to errors.*
Chemical Structure - tamsulosin str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.